Side-by-side · Research reference
SelankvsVilon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticAUTO-DRAFTED11/40 cited
BAnimal-StrongHUMAN-REVIEWED13/49 cited
Selank
Anxiolytic + Cognitive · Russian Pharma
Intranasal · 2–3×/day during stress / cognitive demand
Vilon
Khavinson Bioregulator · Dipeptide
Literature lacks standardised clinical route
01Mechanism of Action
Parameter
Selank
Vilon
Primary target
Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014
Immune cell differentiation pathways, chromatin modification
Pathway
Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007
Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)
Downstream effect
Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007Zaderej 2014
Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011Khavinson 2002Lezhava 2023
Feedback intact?
No GABA-receptor binding; no dependence reportedMedvedev 2007
Unknown — no HPA/HPG axis data
Origin
Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014
Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997
Antibody development
—
—
02Dosage Protocols
Parameter
Selank
Vilon
Standard dose
150–300 mcg / dose intranasalZaderej 2014
No clinical standard — literature lacks human dosing
Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.
Frequency
2–3× per day during stress
Unknown — literature does not specify chronic administration protocols
Lower / starter dose
75 mcg / dose
—
Duration
10–14 day cycles, repeated as needed
Not characterised in humans
Reconstitution
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
—
Timing
Morning + early afternoon preferred
—
Half-life
Short (minutes plasma); CNS effect lasts ~3 hr
Not published — dipeptides typically <10 min plasma t½
Animal model dose
—
In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)
Not translatable to human mg/kg without pharmacokinetic data.
Route
—
Likely SQ or oral (Khavinson school uses both); no published ROA validation
04Side Effects & Safety
Parameter
Selank
Vilon
Nasal irritation
Mild burning or congestion (transient)
—
Cognitive impairment
None — opposite effect (enhancement)
—
Allergic reaction
Rare hypersensitivity
—
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid — insufficient data
—
Human safety data
—
Absent from PubMed-indexed literature
Theoretical risk
—
Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)
Antibody formation
—
Not reported; dipeptides generally low immunogenicity
Animal models
—
No adverse effects noted in mouse thymocyte or pineal lymphoid cultures
Absolute Contraindications
Selank
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Vilon
- ·Active autoimmune disease (theoretical — no clinical data)
Relative Contraindications
Selank
- ·Active autoimmune disease (theoretical via immunomodulation)
Vilon
- ·Pregnancy / lactation (no safety data)
- ·Acute infection with cytokine storm risk (immune modulation unknown)
05Administration Protocol
Parameter
Selank
Vilon
1. Form
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.
2. Administration
Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.
Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.
3. Timing
Morning + early afternoon for cognitive demand; PRN for acute anxiety.
Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.
4. Storage
Refrigerate after reconstitution; ≤30 days. Light-protected.
Likely lyophilised powder, refrigerated. Reconstitution protocols not published.
5. Caveat
Avoid co-administration with strong sedatives or other anxiolytics initially.
—
06Stack Synergy
Selank
— no documented stacks
Vilon
+ Epitalon
ModerateBoth are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.
- Vilon
- Empirical — no standard
- Epitalon
- Empirical — often 10 mg cycles
- Frequency
- Sequential or concurrent (literature ambiguous)
- Primary benefit
- Multi-system aging modulation (immune + pineal/circadian)
+ Thymalin
WeakThymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.
- Vilon
- No standard
- Thymalin
- 10–100 mg IM (polypeptide complex)
- Primary benefit
- Redundant — both target T-cell differentiation